Trastuzumab targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20-30% of breast and ovarian cancers carrying a bad prognosis. Our purpose was to target HER2-overexpressing human breast cancer cells with pegylated immunoliposomes bearing trastuzumab and containing bioactive compounds. Using two breast cancer cell lines, with different HER2 expression levels, these immunoliposomes decreased cancer cells viability in a dose-response manner and in correlation to their level of HER2 expression.
Enhancement of efficacy and selectivity of chemopreventive compounds in human breast cancer cells by using immunoliposomes / Catania, ANGELA MARIA. - (2011 Dec 09).
Enhancement of efficacy and selectivity of chemopreventive compounds in human breast cancer cells by using immunoliposomes
CATANIA, ANGELA MARIA
2011-12-09
Abstract
Trastuzumab targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20-30% of breast and ovarian cancers carrying a bad prognosis. Our purpose was to target HER2-overexpressing human breast cancer cells with pegylated immunoliposomes bearing trastuzumab and containing bioactive compounds. Using two breast cancer cell lines, with different HER2 expression levels, these immunoliposomes decreased cancer cells viability in a dose-response manner and in correlation to their level of HER2 expression.| File | Dimensione | Formato | |
|---|---|---|---|
|
Tesi Angela Catania.pdf
accesso aperto
Tipologia:
Tesi di dottorato
Licenza:
PUBBLICO - Pubblico con Copyright
Dimensione
3.84 MB
Formato
Adobe PDF
|
3.84 MB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
